Literature DB >> 20044598

L1-CAM as a target for treatment of cancer with monoclonal antibodies.

Ulrich H Weidle1, Daniela Eggle, Stefan Klostermann.   

Abstract

L1 cell adhesion molecule (L1-CAM) is a neuronal adhesion molecule which is expressed in many tumor entities. L1-CAM was shown to be involved in proliferation, invasion and metastasis both in vitro and in vivo. L1-CAM is engaged in homophilic interactions and complexes with many other ligands in a context-dependent manner. Activation and modulation of the extracellular signal-related kinase pathway by L1-CAM has been documented. In normal tissues, L1-CAM expression is restricted to nerve bundles and kidney tubules; however, L1-CAM is expressed in many tumor entities and, with the exception of neuroblastoma, L1-CAM expression correlates with poor prognosis. L1-CAM occurs in two isoforms, full-length L1-CAM and a variant in which exons 2 and 27 have been deleted. Preclinical experiments with available monoclonal antibodies are summarized and L1-CAM is analysed as a target for treatment of cancer with monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044598

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

Review 2.  Molecular targets and pathways involved in liver metastasis of colorectal cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2015-06-24       Impact factor: 5.150

Review 3.  Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors.

Authors:  Ulrich H Weidle; Fabian Birzele; Georg Tiefenthaler
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

4.  L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1.

Authors:  Lin Cheng; Qiulian Wu; Zhi Huang; Olga A Guryanova; Qian Huang; Weinian Shou; Jeremy N Rich; Shideng Bao
Journal:  EMBO J       Date:  2011-02-04       Impact factor: 11.598

Review 5.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

6.  L1CAM in the Early Enteric and Urogenital System.

Authors:  Elisabeth Judith Pechriggl; Nicole Concin; Michael J Blumer; Mario Bitsche; Marit Zwierzina; Jozsef Dudas; Katarzyna Koziel; Peter Altevogt; Alain-Gustave Zeimet; Helga Fritsch
Journal:  J Histochem Cytochem       Date:  2016-11-12       Impact factor: 2.479

7.  Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization.

Authors:  Elena Magrini; Alessandra Villa; Francesca Angiolini; Andrea Doni; Giovanni Mazzarol; Noemi Rudini; Luigi Maddaluno; Mina Komuta; Baki Topal; Hans Prenen; Melitta Schachner; Stefano Confalonieri; Elisabetta Dejana; Fabrizio Bianchi; Massimiliano Mazzone; Ugo Cavallaro
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

8.  L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma.

Authors:  Xuan Zhao; Shasha Liu; Xinfeng Chen; Jianyi Zhao; Feng Li; Qitai Zhao; Tan Xie; Lan Huang; Zhen Zhang; Yu Qi; Yang Yang; Song Zhao; Yi Zhang
Journal:  Cancer Biol Med       Date:  2021-03-12       Impact factor: 4.248

9.  Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.

Authors:  Dennis Lindenblatt; Eliane Fischer; Susan Cohrs; Roger Schibli; Jürgen Grünberg
Journal:  EJNMMI Res       Date:  2014-10-03       Impact factor: 3.138

10.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Authors:  Bishoy M Faltas; Davide Prandi; Scott T Tagawa; Ana M Molina; David M Nanus; Cora Sternberg; Jonathan Rosenberg; Juan Miguel Mosquera; Brian Robinson; Olivier Elemento; Andrea Sboner; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Genet       Date:  2016-10-17       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.